Chimerix
Chimerix was a U.S. biopharmaceutical company developing small-molecule oncology therapeutics, principally dordaviprone for recurrent H3 K27M-mutant diffuse glioma. The company was acquired by Jazz Pharmaceuticals in April 2025.
- Company typePrivate
- Founded2000
- HeadquartersDurham, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Chimerix does
Chimerix Inc. was a U.S.-based biopharmaceutical company headquartered in Durham, North Carolina, founded in 2000 and operating with 51–100 employees. The company focused on developing small-molecule therapeutics for serious and life-threatening diseases, with its strategic center of gravity in oncology following the January 2021 acquisition of Oncoceutics, which brought the dordaviprone (ONC201) program into its pipeline.
Chimerix's primary asset was dordaviprone, a small-molecule therapy for recurrent H3 K27M-mutant diffuse glioma — a rare and aggressive brain cancer primarily affecting younger adults and children, with no previously approved treatments. In December 2024, Chimerix submitted a New Drug Application to the FDA seeking accelerated approval with Priority Review, securing a $30 million credit facility from Silicon Valley Bank to support potential commercialization. The company had no product revenue prior to its acquisition.
In April 2025, Jazz Pharmaceuticals completed the acquisition of Chimerix Inc., ending its operation as an independent entity. Post-acquisition, Jazz secured FDA approval of Modeyso (the branded form of dordaviprone) and integrated the program into its oncology franchise. Chimerix's pre-acquisition business model was clinical-stage development: revenue was absent, value creation hinged on regulatory milestones and eventual commercialization, and the customer base was effectively the future H3 K27M-mutant glioma patient population addressed through specialty oncology distribution channels.
Chimerix firmographics
Firmographics- Name
- Chimerix
- Legal name
- Chimerix Inc.
- Website
- https://chimerix.com
- Company type
- Private
- Founded year
- 2000
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- Chimerix was a U.S. biopharmaceutical company developing small-molecule oncology therapeutics, principally dordaviprone for recurrent H3 K27M-mutant diffuse glioma. The company was acquired by Jazz Pharmaceuticals in April 2025.
- Ownership category
- akta.pro rank
Chimerix industry classification
Industry- Product category
- Oncology Pharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where Chimerix is headquartered
LocationHeadquarters
- HQ city
- Durham
- HQ country
- United States
- HQ region
- North America
Markets served
Chimerix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Chimerix product offering
Product offeringCore offering
Chimerix was a biopharmaceutical company developing novel small-molecule therapeutics, with its primary asset being dordaviprone (later approved as Modeyso), a treatment for patients with recurrent H3 K27M-mutant diffuse glioma. The company submitted a New Drug Application to the FDA in December 2024 seeking accelerated approval, with a PDUFA target in Q3 2025, and secured a $30 million credit facility to support potential commercialization.
Product overview
Chimerix was a biopharmaceutical company focused on developing novel small-molecule drugs for the treatment of cancer and other diseases. The company's primary product was dordaviprone (later approved as Modeyso following acquisition by Jazz Pharmaceuticals), a treatment for recurrent H3 K27M-mutant diffuse glioma. Chimerix was acquired by Jazz Pharmaceuticals in April 2025.
Differentiator
Problem solved
Functional benefit
Products and services
- Dordaviprone (later approved as Modeyso) A small-molecule therapeutic candidate for the treatment of patients with recurrent H3 K27M-mutant diffuse glioma, a rare and aggressive brain cancer with no previously approved treatment options. The drug targets the H3 K27M genetic mutation and is intended for both pediatric and adult patients.
Quantifiable outcome
- FDA decision on accelerated approval anticipated in Q3 2025
Companies that use Chimerix
Customer profileSegments1 record
Ideal customer profiles1 record
Chimerix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Chimerix partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Jazz PharmaceuticalscoreJazz Pharmaceuticals completed the acquisition of Chimerix Inc. in April 2025, bringing Chimerix's pipeline including dordaviprone into Jazz's portfolio. Thomas Riga, former Chief Operating and Commercial Officer of Chimerix, joined Jazz as Chief Business Officer following the acquisition and led the sale of Chimerix to Jazz.
Scale indicators3 records
Recent moves6 records
Expansion highlights4 records
Chimerix competitors and assessment
Company assessmentDirect peers
- Kazia Therapeutics: Australia-based oncology biotech developing paxalisib for glioblastoma and other brain cancers. Highly comparable to Chimerix in targeting CNS oncology with a small-molecule therapeutic in late-stage development.
- Medicenna Therapeutics: Clinical-stage immuno-oncology company developing MDNA55 for recurrent glioblastoma. Directly comparable as a brain cancer-focused biotech with a targeted therapeutic platform.
- Diffusion Pharmaceuticals: Developed trans sodium crocetinate for glioblastoma and other solid tumors. Comparable as a small clinical-stage biotech focused on brain cancer therapeutics.
- CNS Pharmaceuticals: Clinical-stage biotech developing berubicin for recurrent glioblastoma. Directly comparable to Chimerix as a small CNS oncology company targeting the same brain cancer patient population.
- DelMar Pharmaceuticals: Focused on developing VAL-083 for newly diagnosed and recurrent glioblastoma. Directly comparable as a small biotech with a single-asset brain cancer therapeutic strategy.
Broad incumbents
- Agios Pharmaceuticals: Established rare disease and oncology company developing therapies for genetically defined conditions, including IDH-mutant cancers. Comparable as a specialty pharma focused on targeted oncology and rare disease.
- Deciphera Pharmaceuticals: Commercial-stage oncology company developing kinase inhibitors for solid tumors. Comparable as an oncology-focused small-molecule developer, though at a more advanced commercial stage.
Emerging players
- Mustang Bio: Clinical-stage cell and gene therapy biotech focused on oncology and rare diseases, including CAR-T programs. Comparable in scale and orphan oncology focus, though using a different therapeutic modality.
- Aprea Therapeutics: Clinical-stage oncology company developing eprenetapopt for TP53-mutant cancers. Comparable to Chimerix as a small-molecule oncology developer focused on genetically defined patient populations.
- Iterion Therapeutics: Emerging oncology company developing tegavivint for desmoid tumors and other cancers. Comparable to Chimerix as a small-cap oncology biotech with a single lead asset.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks6 records
Key highlights7 records
Customer concentration
Chimerix social profiles
Digital presenceChimerix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Chimerix leadership team
Management profileNumber of profiles
Profiles5 records
Chimerix funding detail
Funding detailFunding overview
Funding rounds16 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Chimerix M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Chimerix
What does Chimerix do?
Chimerix was a biopharmaceutical company developing novel small-molecule therapeutics, with its primary asset being dordaviprone (later approved as Modeyso), a treatment for patients with recurrent H3 K27M-mutant diffuse glioma. The company submitted a New Drug Application to the FDA in December 2024 seeking accelerated approval, with a PDUFA target in Q3 2025, and secured a $30 million credit facility to support potential commercialization.
Is Chimerix a public or private company?
Chimerix is a private company. It is classified as corporate owned and is currently acquired.
When was Chimerix founded?
Chimerix was founded in 2000. It employs 51 to 100 people.
Where is Chimerix based?
Chimerix is headquartered in Durham, United States, in the North America region.
Who are Chimerix's main competitors?
Direct peers on record are Kazia Therapeutics, Medicenna Therapeutics, Diffusion Pharmaceuticals, CNS Pharmaceuticals and DelMar Pharmaceuticals. Broad incumbents are Agios Pharmaceuticals and Deciphera Pharmaceuticals. Emerging players are Mustang Bio, Aprea Therapeutics and Iterion Therapeutics.
Does Chimerix have an API?
No public API is recorded for Chimerix.
What industry is Chimerix in?
Chimerix's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.